Cargando...
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
OBJECTIVE: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commercial sponsors in this field and a growing number of...
Gardado en:
| Publicado en: | J Mark Access Health Policy |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Co-Action Publishing
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4973442/ https://ncbi.nlm.nih.gov/pubmed/27570614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.32232 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|